濮阳东方男科医院割包皮收费不高(濮阳东方医院男科网上咨询) (今日更新中)

This illustration provided by Alex Boersma in July 2020 depicts a Kongonaphon kely, a tiny relative of dinosaurs and pterosaurs. Kongonaphon lived roughly 237 million years ago and would have stood only 10 centimeters (4 inches) tall. (Alex Boersma via AP) 264

This year has been incredibly rough for most Americans. This week, former First Lady Michelle Obama said she’s suffering from a “low-grade depression” because of stress from the pandemic, race relations and social justice in the US and the political strife surrounding it all, she says."I'm waking up in the middle of the night because I'm worrying about something or there's a heaviness," Obama said in her "The Michelle Obama Podcast" on Wednesday. "I try to make sure I get a workout in, although there have been periods throughout this quarantine, where I just have felt too low."Obama’s podcast launched at the end of July, her episode on Wednesday was about “Protests and the Pandemic.” She told her guest she has not always felt like getting on the treadmill or waking up at a regular time each morning.“You know, it's a direct result of just being out of, out of body, out of mind. And spiritually, these are not, they are not fulfilling times, spiritually. You know, so I, I know that I am dealing with some form of low-grade depression. Not just because of the quarantine, but because of the racial strife, and just seeing this administration, watching the hypocrisy of it, day in and day out, is dispiriting,” Obama said on her podcast.She then talked about how her family has tried to keep a schedule, to stop what they are doing at 5 p.m. each day and come together to “do an activity” before getting dinner and ready and sitting down as a family.Covid-19 fatigue and a feeling of being overwhelmed is really common right now. Doctors encourage people to try little regular activities, i.e. go for a walk, sit down and have a meal, etc., to feel more in control. 1683

Tinder is soaring thanks to its new premium membership plan: Tinder Gold.Match Group, which owns 45 dating platforms including Tinder, OkCupid and Match.com, reported on Tuesday that Tinder Gold subscriptions boosted sales 19% from a year ago.Tinder added a record 476,000 paying members last quarter. Now 2.5 million customers pay for Tinder.Match CEO Greg Blatt called Tinder's quarter "fantastic" in a prepared statement.Investors swiped right on the report: Shares of Match Group spiked 11% on Wednesday. The stock is up 75% this year.Tinder already had Tinder Plus, which costs .99 a month and allowed customers to increase the number of people who viewed their profiles, use unlimited likes and undo swipes.In August, Tinder debuted Tinder Gold, a .99 monthly subscription that lets customers see who they've matched with as soon as they open the app. Tinder Gold saves time on the app because people don't have to swipe through other profiles to find matches."Tinder Gold plays on people's impatience," says BTIG analyst Brandon Ross.Ross says Match Group has mastered how to make money off loyal Tinder users."They're proving that if you have a deeply engaged base you will eventually get them to spend money," he explained.Still, Match Group faces competition from other dating apps like Bumble, Tastebuds, Hinge and Coffee Meets Bagel and will need to show investors that it's adding new paid subscribers.But analysts are convinced Tinder has room to grow and convert more customers to its paid offerings."There's a lot of momentum that remains behind the broader Tinder story," says Piper Jaffray analyst Sam Kemp.  1646

Too few new antibiotics are under development to combat the threat of multidrug-resistant infections, according to a new World Health Organization report published Tuesday. Adding to the concern: It is likely that the speed of increasing resistance will outpace the slow drug development process.As of May, a total of 51 antibiotics and 11 biologicals -- medical products often made from natural sources -- are being developed, the new report said."The idea is that biologicals could replace use of antibiotics, which could help in overcoming the resistance problem," Peter Beyer, an author of the report and senior adviser to the WHO's Department of Essential Medicines and Health Products, wrote in an email.Seemingly, this large number of potential new drugs should suffice, yet it is not nearly enough.First, just 33 of the antibiotics in the pipeline target priority pathogens. This year, the WHO published a list of a dozen "priority pathogens": 12 separate families of antibiotic-resistant bacteria that pose the greatest threat to human health.Among the priority pathogens is a drug-resistant tuberculosis, which kills about 250,000 people around the world each year, and a variety of multidrug resistant strains -- Acinetobacter, Pseudomonas and various Enterobacteriaceae -- which are responsible for infections in hospitals and nursing homes and among patients whose care requires ventilators and catheters.Of the 33 potential medicines for treating priority bug infections, only eight are innovative treatments. The other 25 are simple modifications of existing families of antibiotics. At best, then, the 25 will serve as short-term solutions since it is expected bacteria will quickly adapt to and resist these new (though somewhat familiar) drugs, according to the WHO."It is difficult to speculate why companies develop specific new medicines," Beyer noted. "But in general many new treatments do not necessarily constitute advances over existing treatments."TB infections require a combination of at least three antibiotics, according to the new report, yet only seven of the new TB medicines are even in clinical trials. Soon, there will be a serious lack of treatment options for this infection, the report warns.The same is true for gram-negative pathogens, which can cause severe, often deadly infections typically in hospitals and nursing homes.Gram-negative bacteria have more complex cell walls than gram-positive, explained Beyer. "In a nutshell, it is more complex to develop a novel antibiotic that can penetrate the complex gram-negative cell wall and stay inside the bacterium," he wrote.Finally, the WHO sees too few oral antibiotics being developed. These are necessary "to target the critical priority pathogens (and) be accessible in low- and middle-income countries," Beyer noted.To address the problem of developing new antibiotics, the WHO and the Drugs for Neglected Diseases Initiative set up the Global Antibiotic Research and Development Partnership. However, new drugs alone cannot combat the threat of antimicrobial resistance. The WHO is also working to improve infection prevention and control while developing guidance for the responsible use of antibiotics."Always seek medical advice before taking antibiotics and then always follow the advice of the health-care professional," Beyer noted.The new report is a "fantastic (and very useful!) summary" of the antibiotic situation, wrote Bill Hanage, an associate professor of epidemiology at Harvard T.H. Chan School of Public Health, in an email. Hanage, who has also published studies of antibiotic resistance, was not involved in the new report.Although the risk of getting a completely resistant infection is low in the United States, about 2 million people each year become infected with "resistant enough" bacteria that are harder to treat, Hanage said. And every year, more than 20,000 people die of these infections."More resistant infections don't just mean you or someone you care about is more likely to die from one, they also mean healthcare will get even more expensive," Hanage said. "Many of the procedures we take for granted in medicine, from cancer treatments to surgeries, depend on our ability to handle infections that happen in the course of treatment."The number of new drugs in development is simply not enough, he said."The great majority will not make it into the hands of doctors or your treatment," Hanage wrote. "As the report states, for drugs to be used in humans they have to pass 3 hurdles, the phase 1, 2 and 3 trials. Drugs entering that pipeline have just a 14% chance of getting all the way through to be used in humans." 4676

Thousands called for a boycott of Goya — the producer of dozens of Latin American staple foods — after the company's CEO praised President Donald Trump at a Thursday event at the White House.At an event prior to his signing of a Hispanic Prosperity Initiative executive order, Trump hosted Latin American leaders at the White House. Among those was Robert Unanue, the CEO of Goya foods, who called the president a "builder," and added that "we are all truly blessed to have a leader like President Trump."Unanue's comments sparked outrage among many, given Trump's past racially-charged against Latin Americans and immigrants. On the day he announced his campaign for the presidency, Trump referred to immigrants from Mexico as "rapists" and "criminals." 762

来源：资阳报